Is Mesalazine Useful in Crohn's Disease?

Challenges in Inflammatory Bowel Disease: Second Edition

Volumn , Issue , 2008, Pages 179-193

  Steinhart, A Hillary ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Crohn's disease; Inflammatory activity index; Inflammatory bowel disease; Mesalazine; Moiety

Indexed keywords

EID: 84889842872     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470753170.ch14     Document Type: Chapter

References (48)

1. Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977;2:892-5.
2. Anthonisen P, Barany F, Folkenborg O, et al. The clinical effect of salazosulphapyridine (Salazopyrin r) in Crohn's disease. A controlled double-blind study. Scand J Gastroenterol 1974;9:549-54.
3. Malchow H, Ewe K, Brandes JW, et al. European cooperative Crohn's disease study (ECCDS): results of drug treatment. Gastroenterology 1984;86:249-66.
4. Rijk MC, van Hogezand RA, van Lier HJ, van Tongeren JH. Sulphasalazine and prednisone compared with sulphasalazine for treating active Crohn disease. A double-blind, randomized, multicenter trial. Ann Intern Med 1991;114(6): 445-50.
5. Singleton JW, Summers RW, Kern F Jr, et al. A trial of sulfasalazine as adjunctive therapy in Crohn's disease. Gastroenterology 1979;77:887-97.
6. Summers RW, Switz DM, Sessions JT Jr, et al. National cooperative Crohn's disease study: results of drug treatment. Gastroenterology 1979;77:847-69.
7. Ursing B, Alm T, Barany F, et al. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden: II. Result. Gastroenterology 1982;83:550-62.
8. Van Hees PA, van Lier HJ, Van Elteren PH, et al. Effect of sulphasalazine in patients with active Crohn's disease: a controlled double-blind study. Gut 1981;22:404-9.
9. Rasmussen SN, Binder V, Maier K, et al. Treatment of Crohn's disease with peroral 5-aminosalicylic acid. Gastroenterology 1983;85:1350-3.
10. Rasmussen SN, Lauritsen K, Tage-Jensen U, et al. 5-Aminosalicylic acid in the treatment of Crohn's diseas. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa. Scand J Gastroenterol 1987;22:877-83.
11. Mahida YR, Jewell DP. Slow-release 5-amino-salicylic acid (Pentasa) for the treatment of active Crohn's disease. Digestion 1990;45:88-92.
12. Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's disease study group. Gastroenterology 1993;104:1293-1301.
13. Singleton JW, Hanauer S, Robinson M. Quality-of-life results of double-blind, placebo-controlled trial of mesalamine in patients with Crohn's disease. Dig Dis Sci 1995;40(5):931-5.
14. Singleton J. Second trial of mesalamine therapy in the treatment of active Crohn's disease. Gastroenterology 1994;107(2):632-3.
15. Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol 2004;2(5):379-88.
16. Tremaine WJ, Schroeder KW, Harrison JM, Zinsmeister AR. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis. J Clin Gastroenterol 1994;19(4):278-82.
17. Thomsen OO, Cortot A, Jewell D, et al. A comparison of budesonide and mesalamine for active Crohn's disease. International budesonide-mesalamine study group. N Engl J Med 1998;339(6):370-4.
18. Campieri M, Ferguson A, Doe W, Persson T, Nilsson LG. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The global budesonide study group. Gut 1997;41(2):209-14.
19. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn's disease. Canadian inflammatory bowel disease study group. N Engl J Med 1994;331(13):836-41.
20. Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994;331(13): 842-5.
21. Gross V, Andus T, Fischbach W, et al. Comparison between high dose 5-aminosalicylic acid and 6-methylprednisolone in active Crohn's ileocoliti. A multicenter randomized double-blind study. German 5-ASA study group. Z Gastroenterol 1995;33(10): 581-4.
22. Martin F, Sutherland L, Beck IT. Oral 5-ASA versus prednisone in short treatment of Crohn's disease: a multicentre controlled trial. Can J Gastroenterol 1990;4:452-7.
23. Prantera C, Cottone M, Pallone F, et al. Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial. Gastroenterology 1999;116(3):521-6.
24. Scholmerich J, Jenss H, Hartmann F. Oral 5-aminosalicylic acid versus 6-methylprednisolone in active Crohn's disease. Can J Gastroenterol 1990;4: 446-51.
25. Modigliani R, Mary JY, Simon JF, et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990;98:811-8.
26. Arber N, Odes SH, Fireman Z, et al. A controlled double blind multicenter study of the effectiveness of 5-aminosalicylic acid in patients with Crohn's disease in remission. J Clin Gastroenterol 1995;20(3):203-6.
27. Bresci G, Petrucci A, Banti S. 5-aminosalicylic acid in the prevention of relapses of Crohn's disease in remission: a long-term study. Int J Clin Pharmacol Res 1991;11(4):200-2.
28. Bresci G, Parisi G, Banti S. Long-term therapy with 5-aminosalicylic acid in Crohn's disease: is it useful? Our four years experience. Int J Clin Pharmacol Res 1994;14(4):133-8.
29. Brignola C, Iannone P, Pasquali S, et al. Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease. Dig Dis Sci 1992;37(1): 29-32.
30. De Franchis R, Omodei P, Ranzi T, et al. Controlled trial of oral 5-aminosalicylic acid for the prevention of early relapse in Crohn's disease. Aliment Pharmacol Ther 1997;11(5):845-52.
31. Gendre JP, Mary JY, Florent C, et al. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Gastroenterology 1993;104(2):435-9.
32. International Mesalazine Study Group. Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's disease. Aliment Pharmacol Ther 1990;4:55-64.
33. Modigliani R, Colombel JF, dupas JL, et al. Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1996;110(3):688-93.
34. Prantera C, Pallone F, Brunetti G, Cottone M, Miglioli M. Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. The Italian IBD study group. Gastroenterology 1992;103: 363-8.
35. Sutherland LR, Martin F, Bailey RJ, et al. A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian mesalamine for remission of Crohn's disease study group. Gastroenterology 1997;112(4):1069-77.
36. Thomson AB, Wright JP, Vatn M, et al. Mesalazine (mesasal/claversal) 1.5 g b.d. vs placebo in the maintenance of remission of patients with Crohn's disease. Aliment Pharmacol Ther 1995;9(6): 673-83.
37. Wellmann W, Schroder U. New oral preparations for maintenance therapy in Crohn's disease. Can J Gastroenterol 1988;2A:71A-2A.
38. Camma C, Giunta M, Rosselli M, Cottone M. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology 1997;113(5):1465-73.
39. Steinhart AH, Hemphill D, Greenberg GR. Sulfasalazine and mesalazine for the maintenance therapy of Crohn's disease: a meta-analysis. Am J Gastroenterol 1994;89(12):2116-24.
40. Messori A, Brignola C, Trallori G, et al. Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: a meta-analysis. Am J Gastroenterol 1994;89(5):692-8.
41. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995;37(5):674-8.
42. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's study group investigators. N Engl J Med 1995;332(5):292-7.
43. Brignola C, Cottone M, Pera A, et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian cooperative study group. Gastroenterology 1995;108(2):345-9.
44. Caprilli R, Andreoli A, Capurso L, et al. Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Aliment Pharmacol Ther 1994;8(1): 35-43.
45. Hanauer SB, Korelitz BI, Rutgeerts P, et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004;127(3): 723-9.
46. Lochs H, Mayer M, Fleig WE, et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European cooperative Crohn's disease study VI. Gastroenterology 2000;118(2): 264-73.
47. McLeod RS, Wolff BG, Steinhart AH, et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology 1995;109(2):404-13.
48. Caprilli R, Cottone M, Tonelli F, et al. Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: a pragmatic, double-blind, randomized controlled trial. Aliment Pharmacol Ther 2003;17(4):517-23.